Europe & the Storm Ahead - Research Report on Seattle Genetics, Inc. and Amarin Corporation
(firmenpresse) - MACAU -- (Marketwire) -- 08/23/11 -- Today, announced its research report highlighting Seattle Genetics, Inc. (NASDAQ: SGEN) and Amarin Corporation (NASDAQ: AMRN). Full content and research is available at .
Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.
As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.
Equity Markets has reviewed Seattle Genetics, Inc. as a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer and autoimmune diseases. The full research report on Seattle Genetics, Inc. (NASDAQ: SGEN) is available here: .
Equity Markets is covering Amarin Corporation as a clinical-stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease. The Company's development programs capitalize in the field of lipid science and the therapeutic benefits of essential fatty acids in cardiovascular disease. The full research report on Amarin Corporation (NASDAQ: AMRN) is available here: .
About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.
Contact:
Samuel Littman
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.08.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 58272
Anzahl Zeichen: 0
contact information:
Town:
MACAU
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Europe & the Storm Ahead - Research Report on Seattle Genetics, Inc. and Amarin Corporation"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Markets Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
